Filgotinib

Drug Profile

Filgotinib

Alternative Names: G-146034; GLPG-0634; GS-6034

Latest Information Update: 04 Mar 2017

Price : $50

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; Gilead Sciences
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antirheumatics; Cyclopropanes; Pyridines; Small molecules; Thiamorpholines; Triazoles
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Ankylosing spondylitis; Psoriatic arthritis

Most Recent Events

  • 10 Mar 2017 Galapagos plans a phase II trial for Crohn's disease (perianal fistulising Crohn's disease) (NCT03077412)
  • 09 Mar 2017 Gilead Sciences plans a phase II trial for Rheumatoid arthritis (Combination therapy) (Gilead Sciences 10-K, February 2017)
  • 27 Feb 2017 Galapago in collaboration with Gilead plans multiple proof-of-concept studies with filgotinib
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top